1. Academic Validation
  2. CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling

CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling

  • Cell Signal. 2022 Sep;97:110393. doi: 10.1016/j.cellsig.2022.110393.
Yan Lu 1 Yijia Shao 1 Yinping Xie 1 Huinan Qu 1 Da Qi 1 Yuan Dong 1 Qiu Jin 1 Liping Wang 1 Junyuan Wei 1 Chengshi Quan 2
Affiliations

Affiliations

  • 1 The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, Jilin 130021, People's Republic of China.
  • 2 The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, Jilin 130021, People's Republic of China. Electronic address: quancs@jlu.edu.cn.
Abstract

Claudin 6 (CLDN6) is an important component of tight junctions. Through the PDZ binding motif, CLDN6 binds to a variety of signaling proteins that contain the PDZ domain to regulate different signaling pathways, and plays an important role in the occurrence and development of tumors. Our previous work showed that CLDN6 was expressed at low levels in breast Cancer cells, and overexpression of CLDN6 inhibited breast Cancer cell proliferation, migration and invasion. However, the mechanism of how CLDN6 works remains unclear. In this study, we aimed to explore the mechanism by which CLDN6 inhibits breast Cancer cell malignant behavior. As a result, overexpression of CLDN6 inhibited the proliferation of breast Cancer cells along with the downregulation of cyclin D1, which plays an important role in regulating cell proliferation. After overexpression of Sp1 in CLDN6-overexpressing cells, the expression of cyclin D1 was upregulated. On the other hand, CLDN6 inhibited breast Cancer cell migration and invasion along with the downregulation of IL-8, CXCR2 and FAK. When treated with IL-8, the migration and invasion ability were promoted along with the upregulation of CXCR2 and p-FAK, and the Cytoskeleton was rearranged in CLDN6-overexpressing cells. Furthermore, when treated with the ERK signaling activator PMA, the proliferation, migration and invasion abilities were promoted along with the upregulation of Sp1, cyclin D1 and IL-8 in CLDN6-overexpressin cells. In conclusion, CLDN6 suppressed ERK/Sp1/cyclin D1 and ERK/IL-8 signaling to inhibit proliferation, migration and invasion in breast Cancer cells. The mechanism may provide experimental evidence for the treatment of breast Cancer targeting CLDN6.

Keywords

Breast cancer; CLDN6; Cyclin D1; ERK; IL-8.

Figures
Products
Inhibitors & Agonists
Other Products